ELYM ELIEM THERAPEUTICS INC

Climb Bio to Present at the 24th Annual Needham Virtual Healthcare Conference

Climb Bio to Present at the 24th Annual Needham Virtual Healthcare Conference

WELLESLEY, Mass., March 27, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM) today announced that members of its executive team will participate at the 24th Annual Needham Healthcare Conference being held virtually April 7-10, 2025.

24th Annual Needham Virtual Healthcare Conference

Format: Presentation and one-on-one investor meetings

Date: April 10, 2025

Time: 8:45 a.m. ET

Webcast: 

About Climb Bio, Inc.

Climb Bio, Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company’s pipeline includes, budoprutug, an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases, and CLYM116, an anti-APRIL monoclonal antibody currently in IND-enabling studies for IgA nephropathy. For more information, please visit . 

Investors

Chris Brinzey

ICR Healthcare



339-970-2843

Media

Jon Yu

ICR Healthcare



475-395-5375



EN
27/03/2025

Underlying

ELYMELIEM THERAPEUTICS INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ELIEM THERAPEUTICS INC

 PRESS RELEASE
Free
ELYM ELIEM THERAPEUT...

Climb Bio Appoints Edgar D. Charles, M.D., MSc as Chief Medical Office...

Climb Bio Appoints Edgar D. Charles, M.D., MSc as Chief Medical Officer Dr. Charles, Accomplished Immunology-Focused Drug Developer, Brings More Than 20 years of Biopharma Leadership, Clinical Development, and Operations Expertise Company Also Hires Cindy J. Driscoll, MBA, Financial Executive with Over Two Decades of Experience Guiding Biotechnology Companies, as Senior Vice President, Finance WELLESLEY HILLS, Mass., June 18, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases...

June 18, 2025 1 EN
 PRESS RELEASE
Free
ELYM ELIEM THERAPEUT...

Climb Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4...

Climb Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) WELLESLEY HILLS, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced that the Company has granted an inducement equity award to a new employee, pursuant to the Company’s 2025 Inducement Plan, as an inducement material to the new employee entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement equity award was granted to one n...

May 19, 2025 1 EN
 PRESS RELEASE
Free
ELYM ELIEM THERAPEUT...

Climb Bio Reports First Quarter 2025 Financial Results and Provides Bu...

Climb Bio Reports First Quarter 2025 Financial Results and Provides Business Updates Clinical Trials of Budoprutug in Primary Membranous Nephropathy (pMN), Immune Thrombocytopenia (ITP), and Systemic Lupus Erythematosus (SLE) on Track to Initiate in 2025 CLYM116 Progressing Towards Anticipated IND or CTA Submission in Second Half 2025 Appointed Kim Cobleigh Drapkin, CPA, and Bo Cumbo as Independent Directors and Perrin Wilson, Ph.D., as Chief Business Officer Strong Financial Position, with Cash Runway Expected Through 2027 WELLESLEY HILLS, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Cli...

May 14, 2025 1 EN
 PRESS RELEASE
Free
ELYM ELIEM THERAPEUT...

Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors

Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors Appointments Include Industry Veterans Kim Cobleigh Drapkin, CPA, and Bo Cumbo as Independent Directors WELLESLEY HILLS, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM) today announced the appointments of biotech industry veterans Kim Cobleigh Drapkin, CPA, and Bo Cumbo to its Board of Directors. Ms. Drapkin will assume the role of Audit Committee Chair, and Mr. Cumbo will assume the role of Compensation Committee Chair. “We are delighted to welcome Kim and Bo to our Board of Directors at Climb B...

April 1, 2025 1 EN
 PRESS RELEASE
Free
ELYM ELIEM THERAPEUT...

Climb Bio to Present at the 24th Annual Needham Virtual Healthcare Con...

Climb Bio to Present at the 24th Annual Needham Virtual Healthcare Conference WELLESLEY, Mass., March 27, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM) today announced that members of its executive team will participate at the 24th Annual Needham Healthcare Conference being held virtually April 7-10, 2025. 24th Annual Needham Virtual Healthcare Conference Format: Presentation and one-on-one investor meetingsDate: April 10, 2025Time: 8:45 a.m. ETWebcast:  About Climb Bio, Inc. Climb Bio, Inc. is a clinical-stage biotechnology company developing therapeutics for patients with im...

March 27, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch